Race Oncology |
High $1.29 |
Low $1.18 |
Trades 155 |
Turnover $303,224 |
Volume 249,053 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (14-Nov) $307,828,256 (417th) |
Close (30-Jun) $1.23 |
Volume (30-Jun) 249,053 |
Shortsold (9-Nov) 19,354 (0.01%) (577th) |
|
52w High $3.79 |
52w Low $1.40 |
P/E - |
EPS -0.06 |
Bisantrene Preclinical Drug Study Published
RAC released this announcement to the ASX on 10 May 2021, 10:24. The announcement is not marked as price sensitive, and is 2 page(s) in length and 311.68kb in size.
You can view all announcements from RAC and see how they appear on a price chart on the announcements page.
At the date of this announcement, RAC was 0.018% short sold according to ASIC data. It was ranked the 548th most shorted stock on the ASX. It remains ranked 577th as of the latest reported data (09 November 2026).
| Other Recent Announcements from RAC | |
|---|---|
| Notification of cessation of securities - RAC | 29 June 2023, 9:54 |
| Proposed issue of securities - RAC | 29 June 2023, 9:52 |
| Initial Director's Interest Notice | 29 June 2023, 9:46 |
| Bisantrene Preclinical Drug Study Published | 10 May 2021, 10:24 |
| Bonus Issue of Options - Letter to Ineligible Shareholders | 7 May 2021, 16:36 |
| Bonus Issue of Options - Letter to Eligible Shareholders | 7 May 2021, 16:36 |
| Proposed issue of Securities - RAC | 5 May 2021, 9:58 |
If you were already registered, log in here.